Oncothyreon reports another tecemotide failure

Oncothyreon's cancer vaccine tecemotide missed another endpoint – this time in a Phase I/II study of Japanese patients with non-small cell lung cancer (NSCLC). The drug has already stalled in development once and the implications for the program are still unclear.

Oncothyreon's cancer vaccine tecemotide missed another endpoint – this time in a Phase I/II study of Japanese patients with non-small cell lung cancer (NSCLC). The drug has already stalled in development once and the implications for the program are still unclear.

A recent filing with the US Securities and Exchange Commission (SEC) revealed that the biotechnology company's partner Merck KGaA has...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category